Dronedarone (Multaq) (Dronedarone (Dronedaron)) and Lurasidone: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A4 inhibition may increase lurasidone exposure. Effects on cardiac rhythm may add when medicines that affect the QT interval are combined.
Clinical significance and safety
Dronedarone (Multaq) and Lurasidone: Moderate CYP3A4 inhibition may increase lurasidone exposure. Effects on cardiac rhythm may add when medicines that affect the QT interval are combined. The relevant antipsychotic information calls for caution with QT-active partners; this is not a claim that it consistently causes clinically important QT prolongation on its own. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.